Source: http://www.google.com/patents/US7854929?dq=6,123,819
Timestamp: 2015-05-27 09:15:15
Document Index: 392138529

Matched Legal Cases: ['Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60', 'Application No. 60']

Patent US7854929 - Method for treating lateral epicondylitis using collagenase - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsMethods for treatment by collagenase injections are provided, which are effective in dissolving and lysing a collagenase septa network to treat carpal tunnel, plantar fasciitis and lateral epicondylitis conditions. The methods treat such conditions by injecting or otherwise delivering purified collagenase...http://www.google.com/patents/US7854929?utm_source=gb-gplus-sharePatent US7854929 - Method for treating lateral epicondylitis using collagenaseAdvanced Patent SearchPublication numberUS7854929 B2Publication typeGrantApplication numberUS 12/115,256Publication dateDec 21, 2010Filing dateMay 5, 2008Priority dateJan 21, 2005Fee statusPaidAlso published asUS20090010918Publication number115256, 12115256, US 7854929 B2, US 7854929B2, US-B2-7854929, US7854929 B2, US7854929B2InventorsMarie A. Badalemente, Edward WangOriginal AssigneeThe Research Foundation Of State University Of New YorkExport CitationBiBTeX, EndNote, RefManPatent Citations (4), Non-Patent Citations (6), Referenced by (4), Classifications (11), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetMethod for treating lateral epicondylitis using collagenase
US 7854929 B2Abstract
Methods for treatment by collagenase injections are provided, which are effective in dissolving and lysing a collagenase septa network to treat carpal tunnel, plantar fasciitis and lateral epicondylitis conditions. The methods treat such conditions by injecting or otherwise delivering purified collagenase to the afflicted region of the patient, as well as use of collagenase for manufacture of a medicament for such conditions.
This application claims priority to U.S. Provisional Application No. 60/927,437, filed May 3, 2007, to U.S. Provisional Application No. 60/934,045, filed Jun. 11, 2007, to U.S. Provisional Application No. 60/934,046, filed Jun. 11, 2007, to U.S. Provisional Application No. 60/645,772 filed on Jan. 21, 2005, to U.S. Provisional Application No. 60/677,440 filed on May 3, 2005 and U.S. Provisional Application No. 60/719,470 filed on Sep. 22, 2005, and is a continuation in part of U.S. application Ser. No. 11/703,269, filed with the U.S. Patent and Trademark Office on Feb. 7, 2007, and is a continuation in part of U.S. application Ser. No. 11/335,157, filed with the U.S. Patent and Trademark Office on Jan. 19, 2006, the contents of each of which is incorporated herein by reference.
The invention was supported, in part, by a grant M01RR10710 from the National Institutes of Health. The U.S. Government may have certain rights in the invention.
Numbness of the fingers and parasthesia are common symptoms of Carpal Tunnel Syndrome (“CTS”). A stressed-median nerve coupled with increased compression accompanying bending of the wrist creates numbness and tingling. CTS can result in difficulty gripping and making a fist, and dropping objects. Conventional remedies for CTS include non-steroidal anti-inflammatory mediations, splinting at night and sometimes corticosteroid injection of the carpal canal. CTS can also treated surgically, either endoscopically or by open surgery. In contrast to the invasive and disruptive conventional treatments of CTS, the present invention treats CTS by collagenase injection directed at the transverse carpal ligament.
The present invention relates to the discovery that collagenase injections are effective in providing purified collagenase to collagenous adhesions of a finger and other joints and afflicted areas to provide a method for non-surgical treatment of CTS, of collagenous elbow and/or knee joint adhesions, and to dissolve fibrous adhesions in a sole of a patient's foot to non-surgically treat plantar fasciitis.
The present invention is related to the discovery of the effectiveness of collagenase injections. That is, the present invention relates to treating a patient by injecting an effective amount of collagenase to affected regions of carpal tunnel, plantar fasciitis and lateral epicondylitis conditions. The present invention also relates to the use of collagenase in the manufacture of a medicament to treat carpal tunnel, plantar fasciitis and lateral epicondylitis conditions.
The published work of the inventor, Dr. Badalamente, in Dupuytren's disease forms the rationale for the present invention (Starkweather, K., Lattuga, S., Hurst, L. C., Badalamente, M. A., Guilak, F., Sampson, S. P., Dowd, A., Wisch, D. Collagenase in the Treatment of Dupuytren's Disease: An in vitro Study, J. Hand Surg. 21A:490-95, 1996; Badalamente, M. A., Hurst, L. C., Enzyme Injection as a Non-operative Treatment for Dupuytren's Disease, J. Drug-Delivery 3(1):35-40, 1996; Hurst, L. C., Badalamente, M. A. (invited authorship) Non-operative Treatment of Dupuytren's Disease, Hand Clinics, G. M. Rayan (ed). W.B. Saunders 15(1), 97-107, 1999; Hurst, L. C., Badalamente, M. A. (invited editors & authorship), Dupuytren's Disease, R. Tubinana, R. Tubiana, C. Leclercq, L. C. Hurst, M. A. Badalamente (eds), Martin Dunitz Publisher, London (2000); Badalamente, M. A., Hurst, L. C. Enzyme Injection as a Non-operative Treatment of Dupuytren's Disease, J. Hands Surg. 25A(4); 629-36, 2000; Badalamente, M. A., Hurst, L. C., Hentz, V. R. Collagen as a Clinical Target: Non-operative Treatment of Dupuytren's Disease, J. Hand Surg. 27A(5):788-98, 2002, Badalamente, M. A., Hurst, L. C. Efficacy and Safety of Injectable Mixed Collagenase Subtypes in the Treatment of Dupuytren's Contracture, J. Hand. Surg. 32A(6): 767-774, 2007). In Dupuytren's disease, the pathognomonic fibrous cord is often interspersed with a septa-like arrangement of adipose tissue. These present clinically as mattress-type “lumps” of varying sizes, and in Dupuytren's disease, are termed nodules. It has been a consistent clinical finding in both Phase 2 and 3 trials for Dupuytren's disease that after purified Clostridial collagenase injection, not only does the collagenous cord dissolve and rupture when subjected to pressure in extension, but the fibro-fatty nodules also resolve, and harmlessly resorb. Therefore, collagenase injected subcutaneously into afflicted areas was postulated to be a safe and effective treatment.
One form of purified collagenase used for injection is comprised of two microbial collagenases, referred to as “Collagenase ABC I” and “Collagenase ABC II”. Both collagenases are isolated and purified from the fermentation of the bacterium Clostridium hisolyticum and belong to the same metalloprotease.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4524065Aug 4, 1983Jun 18, 1985Bio-Specifics N.V.Method for the prevention and treatment of scars with enzymesUS4645668Mar 27, 1985Feb 24, 1987Biospecifics, NvMethod for the prevention and treatment of scars with enzymesUS6335388Oct 2, 1998Jan 1, 2002Lavipharm Laboratories Inc.Prolamine-plant polar lipid composition, its method of preparation and applications thereofUS6358539Aug 18, 2000Mar 19, 2002Howard MuradPharmaceutical compositions for reducing the appearance of celluliteNon-Patent CitationsReference1Badalamente, Marie A., et al. "Efficacy and Safety of Injectabel Mixed Collagenase Subtypes in the Treatment of Dupuytren's Contracture," The J. of Hand Surgery, 32A(6):767-774 (2007).2 *Galardy et al..(Biochemistry, vol. 22, pp. 4556-4561, 1983).3Health News, WebMD, pp. 1-2 (2006).4 *Jung et al. ( J. of Bacteriology, vol. 181, No. 9, pp. 2816-2822, 1999).5Rotunda, Adam, M. et al., "Mesotherapy and phosphatidycholine injections: historical clarification and review," Dematologic Surgery: Official Publication for American Society for Dermatologic Surgery [et al.] 32(4):465-480 (2006).6SurgerNews.Net, pp. 1-3, Apr. 2005.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8323643Nov 6, 2008Dec 4, 2012The Research Foundation Of State University Of New YorkMethods for treating adhesive capsulitisUS8702654 *Mar 25, 2010Apr 22, 2014John M. AgeeTreatment of carpal tunnel syndrome by injection of the flexor retinaculumUS20100247513 *Mar 25, 2010Sep 30, 2010John M. Agee, Trustee Of The John M. Agee Trust Of August 15, 1996Treatment of carpal tunnel syndrome by injection of the flexor retinaculumWO2012125948A1Mar 16, 2012Sep 20, 2012Biospecifics Technologies Corp.Compositions and methods for producing clostridial collagenases* Cited by examinerClassifications U.S. Classification424/94.67, 435/7.1, 514/17.2International ClassificationA61K38/48Cooperative ClassificationA61Q19/06, A61K2800/91, A61K38/4886, A61K8/66European ClassificationA61K38/48N, A61K8/66, A61Q19/06Legal EventsDateCodeEventDescriptionApr 10, 2014FPAYFee paymentYear of fee payment: 4Apr 20, 2011ASAssignmentOwner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OFFree format text: CONFIRMATORY LICENSE;ASSIGNOR:STATE UNIVERSITY NEW YORK STONY BROOK;REEL/FRAME:026152/0947Effective date: 20110414Mar 29, 2011CCCertificate of correctionSep 22, 2008ASAssignmentOwner name: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEWFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BADALEMENTE, MARIE A.;WANG, EDWARD;REEL/FRAME:021562/0225;SIGNING DATES FROM 20080519 TO 20080901Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BADALEMENTE, MARIE A.;WANG, EDWARD;SIGNING DATES FROM 20080519 TO 20080901;REEL/FRAME:021562/0225Owner name: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEWFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BADALEMENTE, MARIE A.;WANG, EDWARD;SIGNING DATES FROM 20080519 TO 20080901;REEL/FRAME:021562/0225RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services